0QW0.LSE

Argen-X

0QW0.LSE, UK

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

https://argenx.com

Stock Price

€0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
0QW0.LSE
stock
0QW0.LSE

arGEN X (0QW0) Gets a Buy from Bank of America Securities The Globe and Mail

Read more →

Finn Analysis

(Last Updated 2024-12-31)

Health Score

Price to Book Ratio (P/B)

-

Very High

9.34

Low 1

High 3

Return on Equity (ROE)

-

Medium

15.74 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very High

13.96 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

3.03 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.13

Low 1

High 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Argen-X

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

3.83

Latest Release

Date

2025-09-30

EPS Actual

4.48

EPS Estimate

4.3

EPS Difference

0.18

Surprise Percent

4.186%

Investing Fit Scorecard

(Last Updated 2024-12-31)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(10)
GARP
Strong GARP(9.5)
Growth
High Growth(7.5)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(4)
Quality
High Quality(9)
Value
Undervalued(7)

Income Statement

(Last Updated 2024-12-31)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-12-31)

Cash

0

Short Term Investments

0

Receivables

0

Inventories

0

Total Current Assets

0

Property Plant Equipment

0

Total Assets

0

Payables

0

Short Term Debt

0

Long Term Debt

0

Total Liabilities

0

Equity

0

Trend

Cash Flow

(Last Updated 2024-12-31)

Net Income

0

Depreciation

0

Change In Working Capital

0

Cash From Operations

0

Capital Expenditures

0

Cash From Investing

0

Cash From Financing

0

Net Change In Cash

0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.